Latest Life Biosciences News & Updates

See the latest news and media coverage for Life Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Life Biosciences

Biotechnology company developing cellular rejuvenation therapies

lifebiosciences.com

Headquarters: Boston, United States
Founded year: 2017
Company type: Private company
Number of employees: 27–50
Industry: Biotechnology & Medical Research

Last updated October 8

Latest news about Life Biosciences

In short: Life Biosciences reported positive Phase 1 ER-100 data and raised $80 million in Series D financing.

Company announcements

October 8 Life Biosciences

Life Biosciences reports positive Phase 1 ER-100 data for glaucoma

The trial showed ER-100 was well-tolerated with no serious adverse events. Visual improvements occurred in two participants, prompting DSMB approval to escalate the dose.

June 9 Life Biosciences

Life Biosciences dosed first patient in Phase 1 trial

The trial evaluates ER-100 for optic neuropathies including glaucoma and NAION, targeting root cause of age-related vision loss.

April 8 Life Biosciences

Life Biosciences secures $80 million Series D financing

Funding supports Phase 1 trial of ER-100 for optic neuropathies and advances Partial Epigenetic Reprogramming platform. Announced April 8, 2026.

January 28 Life Biosciences

Life Biosciences announces FDA clearance of IND for ER-100

The clearance enables a Phase 1 trial for ER-100, a cellular rejuvenation therapy, in optic neuropathies like glaucoma and NAION.

Media coverage

September 30 BioSpace

Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies

Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of ...

July 5 Telegraph-Herald

World’s first cell‑rejuvenating therapy given to patient | Features | telegraphherald.com

The experimental treatment by Life Biosciences will deliver three distinct genetic edits to regenerate neurons in the optic nerve, which can be damaged in people...

June 16 MSN

World's first cell‑rejuvenating therapy given to patient

A Boston company treated its first patient with a therapy intended to allow aging optic nerve cells to behave as though they were young again...

June 9 WIRED

Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.

Never miss news about Life Biosciences

Track Life Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Life Biosciences competitors & trending companies

Browse news for competitors to Life Biosciences and other trending companies.